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Abstract
Objective: Establishing a core set of outcomes to be evaluated and reported in inter-
vention trials aims to improve the usefulness of health research. There is no estab-
lished core outcome set (COS) for childhood epilepsies. The aim of this study was to 
select a COS to be used in evaluative research of interventions for children with ro-
landic epilepsy (RE).
Methods: We followed guidance from the COMET (Core Outcome Measures in 
Effectiveness Trials) Initiative. First, we identified outcomes that had been measured 
in research through a systematic review. Second, young people with RE, parents, and 
professionals were invited to take part in a Delphi survey in which participants rated 
the importance of candidate outcomes. Last, a face‐to‐face meeting was convened to 
seek consensus on which outcomes were critical to include and to ratify the final COS.
Results: From 37 eligible papers in the review, we identified and included 48 candi-
date outcomes in the survey. We sent invitations to 165 people registered to take part 
in the survey; of these, 102 (62%) completed Round 1, and 80 (78%) completed 
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1 |  INTRODUCTION
Epilepsy is a common neurological disorder that can be 
defined by a persisting tendency for epileptic seizures. 
Epilepsy encompasses many different conditions, includ-
ing around 30 different epilepsy syndromes and affects 
people of all ages, including children.1 Seizure reduction, 
freedom from seizures, and a significant reduction in dura-
tion and intensity of seizures are typical primary outcomes 
in trials evaluating interventions for epilepsy. However, it 
is important to consider the adverse effects of antiepileptic 
medication as well as nonseizure outcomes, particularly in 
developing children.
The social and psychological consequences of seizures 
and children's perspectives are becoming more valued, and 
health‐related quality of life (HRQoL) is an increasing 
focus for research.2 It is important to consider that epi-
lepsy‐specific quality of life is not determined by seizures 
alone but can also be influenced by the child's learning, 
mental health, and social support.3,4 To overcome these 
issues, it is crucial to decide on a core set of outcomes that 
are of greater importance to children and their families.
The variety of outcomes assessed in research and the dif-
ferent ways outcomes are measured can reduce the ability to 
combine and compare studies.5 Recognizing a core set of out-
comes to be measured and reported in all trials of interven-
tions for specific conditions aims to advance the usefulness of 
research and avoid waste.6‒8 A core outcome set (COS) that 
recommends the same suite of outcomes measured in the same 
way reduces both heterogeneity between studies and outcome 
reporting bias. It can also increase the potential for carrying 
out meta‐analysis for important outcomes. The development of 
a COS should include the views of patients, carers, and health 
professionals.7 A COS may also be useful for other types of re-
search, clinical audit, and structuring routinely collected health 
services clinical data. A COS specifies which aspects of health 
are to be assessed and how to measure them.
Currently, there is no COS for evaluative research of in-
terventions in children with epilepsy. The Core Outcome 
Measures in Effectiveness Trials (COMET) Initiative da-
tabase recently added a study focused on West syndrome9 
and a study conducted in Sri Lanka on the development of 
outcome criteria to measure effectiveness of antiepileptic 
medication.10 The National Institute for Health Care and 
Excellence guidelines recommend seizure freedom as a pri-
mary outcome alongside seizure reduction, quality of life, and 
cognitive functioning as secondary outcomes.11 Cochrane 
reviewers advise focusing on longer‐term outcomes such 
as psychosocial and health economic outcomes.12 Scottish 
guidance recommends including aspects of academic attain-
ment and mental health outcomes13 and the International 
League Against Epilepsy (ILAE) has published guidance on 
outcome measurement for clinical trials.14,15 Children are 
included in the Common Data Elements recommended for 
epilepsy research by the National Institute of Neurological 
Disorders and Stroke (NINDS).16 The NINDS recommends 
a comprehensive list of items across various domains, but 
children and parents were not consulted in the process.16
Myoclonic Epilepsy (201503MOP‐342469, 
D.K.P.); the European Union Program of 
the Seventh Framework: Development 
of Strategies for Innovative Research 
to Improve Diagnosis, Prevention and 
Treatment in Children With Difficult 
to Treat Epilepsy, “DESIRE” (602531, 
D.K.P.); a Medical Research Council 
Centre Grant (MR/N026063/1, D.K.P.); 
a Waterloo Foundation Project Grant 
(164‐3020, D.K.P.); the Charles Sykes 
Epilepsy Research Trust (D.K.P.); and the 
NIHR Specialist Biomedical Research 
Centre for Mental Health of South London 
and Maudsley National Health Service 
Foundation Trust (D.K.P.).
Round 2 (three young people, 16 parents, 61 professionals). In Round 2 we included 
four additional outcomes suggested by participants in Round 1. The consensus meet-
ing included two young people, four parents, and nine professionals who were eligi-
ble to vote and ratified the COS as 39 outcomes across 10 domains.
Significance: Our methodology was a proportionate and pragmatic approach toward 
producing a COS for evaluating research on interventions aiming to improve the 
health of children with RE.
K E Y W O R D S
children, core outcome set, epilepsy, pediatric, young people
Key Points
• There was no established core outcome set for 
childhood epilepsy
• Consensus‐based methods were used to rate the 
importance of different outcomes in rolandic epi-
lepsy; this included two rounds of a Delphi survey 
and a face‐to‐face meeting that included young 
people with rolandic epilepsy, parents, and vari-
ous professionals
• We identified 39 outcomes across 10 domains that 
contributed toward a core outcome set for use in 
epilepsy research
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The aim of this study was to develop a COS relevant to 
evaluative research on interventions for children with rolan-
dic epilepsy (RE), as an exemplar of common childhood ep-
ilepsy syndromes. RE is also known as “childhood epilepsy 
with centrotemporal spikes” in the revised ILAE classifica-
tion.1 RE is the most common childhood epilepsy, affecting 
17%‐25% of children with epilepsy in the 5‐ to 14‐year age 
range.17‒19 The syndrome is associated with specific neuro-
psychological impairments such as in speech and language, 
literacy, and attention as well as motor coordination defi-
cits but is not associated with autism spectrum disorder or 
intellectual disability.20‒22 Our study focused on children 
of school age (5‐16 years old) with RE, and our protocol is 
published.23 Specifically, our objectives were to review pub-
lished research to identify outcomes reported in research and 
to seek consensus on which outcomes were perceived to be 
most important to measure in research. The work was con-
ducted in partnership with families, health professionals, and 
epilepsy charities in the UK.
Our work is motivated by the necessity to change the 
agenda from a seizure‐centered medical model toward 
broader child and family priorities and to focus scarce re-
sources on the most important outcomes.24 Our primary aim 
was to propose a COS for evaluative trials, but the findings 
may also inform decisions on outcomes measured in audits 
and/or routinely collected services data. The scope of this 
study included outcomes of any medical or social interven-
tion where the aim was to improve the health of children with 
epilepsy and was not limited to medication. This study is part 
of a program of work aiming to improve broad HRQoL for 
children with epilepsy. The COS will inform decisions about 
outcomes to be measured in a future clinical trial evaluating 
interventions for RE scheduled to begin recruitment in 2019.
2 |  MATERIALS AND METHODS
2.1 | Ethics and registration
The study was conducted in line with COMET meth-
odological recommendations,25 with a published proto-
col23 and was registered on the COMET database (www.
comet-initiative.org/studies/details/1030). Our study was 
approved by the National Health Service (NHS) Health 
Research Authority (North East–Newcastle & North 
Tyneside 1 Research Ethics Committee, reference 18/
NE/0014). Participants registered for the Delphi survey 
through our website (www.castlestudy.org.uk). Taking 
part in the Delphi was regarded as implicit consent. Young 
people took part in the Delphi if their parents agreed and 
provided them with the online Delphi link. Written consent 
was gathered at the face‐to‐face consensus meeting for par-
ents, young people, and professionals. The study is reported 
in line with COS‐STAR (Core Outcome Set–Standards 
for Reporting) guidance26 and the GRIPP2 short form for 
Patient and Public Involvement (PPI)27 and the review is 
reported with reference to PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta‐Analyses).28
To develop the COS, we undertook three steps: (1) iden-
tifying candidate outcomes, (2) rating the importance of 
candidate outcomes in a two‐round Delphi survey, and (3) a 
face‐to‐face consensus meeting to ratify results of the Delphi 
survey and agree core outcomes. We convened an advisory 
panel (AP) of young people with epilepsy and their carers 
alongside to consult on various decisions throughout each 
step.
2.1.1 | Step 1. Identifying 
candidate outcomes
We identified candidate outcomes via structured, system-
atic review methods described in our protocol.23 Briefly, 
we looked for (1) primary evaluations and systematic re-
views of interventions for RE, (2) qualitative or mixed 
methods studies about experiences and preferences for 
outcomes, and (3) epilepsy‐specific and generic patient‐re-
ported outcome measures used with children with epilepsy. 
We searched for systematic reviews using terms for RE or 
childhood epilepsy in the Cochrane Database of Systematic 
Reviews, MEDLINE (via OvidSP), Embase (via OvidSP), 
PsycINFO (via OvidSP), and CINAHL (via EBSCOhost). 
We searched for controlled trials via the CENTRAL da-
tabase and checked previously found systematic reviews 
for additional relevant trials. We also searched the World 
Health Organization International Clinical Trials Registry 
Platform for ongoing trials. Finally, we searched for quali-
tative or mixed methods research on MEDLINE, CINAHL, 
and PsycINFO using terms for epilepsy combined with 
terms for qualitative research, experience, and HRQoL. 
The electronic search was carried out in October 2017 
by M.R. (Appendix S1). H.C. reviewed and screened the 
abstracts and selected references. Decisions on eligibility 
where there was uncertainty were made in consultation 
with two other reviewers (C.M. and D.K.P.). As outlined 
in our protocol,23 two people did not screen the references 
independently, because the additional resources were not 
justified by the risk of missing outcome domains, as we 
expected considerable duplication. H.C. coded outcomes 
extracted from the papers in consultation with C.M. using 
the COMET taxonomy29; any doubts about coding were re-
solved in consultation with the wider team. H.C. extracted 
and entered information from the papers into spreadsheets, 
including population, outcomes, measurement instruments, 
and any other salient information, and then this summa-
rized in table form (Appendix S2). We did not assess risk 
of bias for included studies, as this was not relevant to the 
aim of this study.
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2.1.2 | Step 2. Rating the importance of 
outcome domains in a two‐round Delphi survey
The outcome domains identified in step 1 were taken for-
ward for importance rating in a Delphi survey. We con-
ducted the online Delphi survey over two rounds (R1 and 
R2) using DelphiManager software.30 Our protocol pro-
posed three rounds, but we shortened this to two rounds to 
reduce potential attrition and mitigate time constraints. We 
recruited participants from three key stakeholder groups: 
young people with RE aged 7‐16 years, parents of children 
with RE, and professionals working with this group of chil-
dren (pediatricians, pediatric neurologists, epilepsy special-
ist nurses, etc). We recruited participants through various 
platforms, including epilepsy charities, professional socie-
ties, and regional networks via OPEN UK (Organisation of 
Paediatric Epilepsy Networks). We posted advertisements 
on social media platforms (eg, Facebook and Twitter). Four 
NHS hospitals were set up as participant identification 
centers to enable clinicians to recruit patients, parents, and 
colleagues. We directed interested participants to the study 
website, where they could register using an online form.
Participants were asked to rate the importance of each 
outcome in the Delphi survey using a scale from 1 to 9 in 
which options 1‐3 were labeled “less important,” options 4‐6 
were “important but not critical,” and options 7‐9 indicated 
“critical for inclusion” in the COS. Participants were able to 
suggest additional outcomes in R1, which were considered 
by the core team members for inclusion in R2 (Appendix 
S4). We considered whether the suggested outcomes were 
actually different from the concepts already covered in the 
existing Delphi and whether they had been suggested by 
more than one person. In R2, participants were shown the 
distribution of other stakeholders’ scores from R1 in histo-
grams as well as their own R1 score. They were asked to 
use this information to reflect on their score and rate the 
outcome again. Participants were able to give reasons for 
changing their score and leave free text comments.
We sent the Delphi survey link to people who registered in-
terest online with a valid email address. R1 and R2 were open 
for 2 weeks each with a 1‐week interval in between. After R2 
closed, we downloaded the participant data and converted 
them into the percentage of stakeholders scoring from 1 to 9 
across all outcomes. Our predefined consensus criteria were 
(1) most important “core” outcomes agreed by most stake-
holders (>70% in each stakeholder group rated 7‐9), (2) less 
important outcomes (>70% in each stakeholder group rated 
1‐3), and (3) those where there was partial or no agreement.
2.1.3 | Step 3: Consensus meeting
Results from R2 of the online Delphi (Table 3) were shown at 
a face‐to‐face half‐day meeting in London. We sent invitations 
to participants who had completed both R1 and R2 of the 
Delphi. We encouraged parents to bring their children to the 
meeting if their child had also taken part in the Delphi. Travel 
costs were reimbursed on behalf of participants as well as a 
payment given to nonsalaried individuals. All three stake-
holder groups were represented at the meeting (Appendix S5). 
A member of the research team (C.M.) chaired the meeting, 
and ground rules were agreed to ensure that all participants felt 
comfortable about speaking out in the group.
Outcomes that had met the a priori criteria of “consen-
sus in” from the Delphi were initially displayed; all partic-
ipants agreed that no further discussion was needed about 
their inclusion in the COS. All the remaining “no consen-
sus” outcomes were displayed and discussed at the meet-
ing. We gave participants red and green cards to vote with. 
Holding up a red card meant that the outcome was not im-
portant enough to include in the COS. Holding up a green 
card meant that the participant thought it critical that the 
outcome be included. The chair ensured that contrasting 
views about voting were discussed and that equal oppor-
tunity was given to participants to discuss their voting de-
cisions. Outcomes meeting the criteria for “consensus in” 
during the meeting were incorporated into the COS. The 
final COS was presented and ratified to the group via email 
after the meeting so that people could have further time to 
think about their decisions and confirm.
2.2 | Patient and public involvement
Two parents of children with epilepsy were coapplicants when 
we sought funding for the program of research within this 
nested study and are coinvestigators. A Family Engagement 
Officer (FEO) convened an AP in the south of England to in-
volve young people and parents as meaningful partners in the 
development and implementation of our research. The FEOs 
recruited young people with epilepsy and their parents through 
various UK charities (Young Epilepsy, Epilepsy Action, 
Epilepsy Research UK), clinical networks (including consult-
ant clinics and epilepsy specialist nurses), word‐of‐mouth, 
online parent forums, and social media groups. We consulted 
AP members through face‐to‐face meetings and also remotely 
using email and telephone. The AP members were involved in 
reviewing the Core Health Outcomes in Childhood Epilepsy 
(CHOICE) documents sent to the ethics committee and the 
Delphi survey. Members of the AP were asked to consider 
ease of the instructions and use of the survey.
AP members provided insight as to the ease of the Delphi 
survey and the relevance of outcomes. Modifications were 
made to the Delphi survey based on AP feedback, and some 
wording for Delphi instructions were changed. Two parent 
lay coapplicants (D.R., J.C.) were part of the consensus meet-
ing alongside the southern England FEO who helped to facil-
itate the contribution of parents and children in the meeting.
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3 |  RESULTS
3.1 | Step 1: Identifying candidate outcomes
Thirty‐seven papers were included in the review (Figure 1); 
181 outcomes were recorded verbatim. A provisional list 
of 177 outcomes (Appendix S2) was reviewed at a face‐to‐
face meeting. There were a large number of outcomes that 
overlapped considerably, so outcomes were coded using the 
COMET taxonomy29 into the following domains: physi-
ological nervous system outcomes, physical functioning, 
social functioning, role functioning, emotional functioning/
well‐being, cognitive functioning, global quality of life, and 
adverse events/effects. Similar outcomes were discussed and 
aggregated at the meeting that resulted in 48 overall out-
comes for inclusion in R1 of the Delphi survey (Table 1). 
Each outcome was given a lay domain name and description 
for use in the survey. The descriptions were agreed upon with 
two parent lay coapplicants at the study meeting.
3.2 | Step 2: Delphi survey
One hundred sixty‐five people registered interest through our 
study website. Of the 165 interested people, 102 participants 
took part in R1 (professionals, n = 76, 75%; parents, n = 23, 
20%; young people, n = 3, 3%), and 80 from R1 completed 
R2 (professionals, n = 61, 76%; parents, n = 16, 20%; young 
people, n = 3, 4%; Table 2). The majority of people who 
completed R2 were from London (professionals, 30%; parents 
and young people, 21%), with full demographics of partici-
pants available in Appendix S3. One professional withdrew 
from the study in R1 due to work commitments. Four people 
did not fully answer R1 questions, and only the questions they 
answered were included in the analysis. Twenty‐two people 
did not fully complete R2 questions despite logging in, and 
only the questions they answered were analyzed. R1 and R2 
of the Delphi were open for 2 weeks, with a 1‐week gap in be-
tween the rounds to allow the histograms to be created and up-
loaded for R2. Forty‐eight outcomes were rated in R1 (Table 
1) and an additional 19 outcomes were suggested in R1, of 
which four were brought forward based on predefined deci-
sions (Appendix S4). After the close of the Delphi survey, 11 
outcomes met the a priori condition for “consensus in” from 
R2. Delphi R1 and R2 scores are shown in Table 3. The attri-
tion rate from R1 to R2 was 22% overall (33% of parents, 20% 
of professionals, 0% of young people), displayed in Table 2.
3.3 | Step 3: Consensus meeting
Nineteen people were present at the face‐to‐face consensus 
meeting, and 15 were eligible to vote: two young people 
(aged 11 and 12 years), four parents, and nine profession-
als (two pediatricians, two pediatric neurologists, two sleep 
consultants, one clinical psychologist, one physiologist, 
and one professor of children's nursing), with information 
F I G U R E  1  PRISMA (Preferred 
Reporting Items for Systematic Reviews 
and Meta‐Analyses) flowchart of literature 
review
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T A B L E  1  Outcomes used in R1 & R2 of the Delphi survey
Outcome ID and name in Delphi Description Domain name
1. Seizure freedom Not having seizures Seizures
2. Seizure frequency How often seizures occur Seizures
3. Seizure duration How long a seizure lasts Seizures
4. Seizure severity How bad seizures are in terms of effects on the person during and 
after seizures, such as falls or injuries, incontinence, confusion, 
and time to recover afterward
Seizures
5. Time to fall asleep Time it takes to fall asleep from snuggling down Sleep
6. Time spent asleep Total time spent asleep each day Sleep
7. Awakenings Waking in the night that parents/carers are aware of Sleep
8. Breathing difficulties during sleep Might include snoring or gasping for breath Sleep
9. Daytime sleepiness Feeling sleepy or actually sleeping during the day Sleep
10. Fatigue Lacking in energy Physical functioning
11. Pain Unpleasant physical sensation Physical functioning
12. Coordination and balance Using parts of the body together and efficiently, such as to ride a 
bike, stand on one leg, catch and throw
Physical functioning
13. Movement ability Walking, running, jumping, hopping Physical functioning
14. Manual ability Dexterity in handling objects, handwriting Physical functioning
15. Self‐care Daily routines such as eating, washing and dressing, toileting Usual activities
16. Ability to join in activities with others Joining in with people, such as playing out withfriends, doing 
sports, joining in things
Social functioning
17. Ability to play on one's own Reading, computer, imaginary play Social functioning
18. Friendships Forming and maintaining friendships Social functioning
19. Engagement in school life Feeling part of the school community Social functioning
20. Social life Engagement with friends and peers, such as going out, sleepovers, 
cinema
Social functioning
21. Experience of people's attitudes toward 
epilepsy
Bullying, social exclusion Social functioning
22. Behaving appropriately Being able to control emotions and respond to situations in context Behavior
23. Impulsivity Acting without thinking Behavior
24. Fidgeting Restless, being on the go, moving or squirming Behavior
25. Feeling normal Feeling like other people of the same age Mental health
26. Feelings about having epilepsy Emotions or reactions to having epilepsy, such as embarrassment, 
shame, stigma
Mental health
27. Happiness Feeling or showing pleasure or contentment Mental health
28. Sadness Feeling or showing sorrow or being unhappy Mental health
29. Worried Being anxious or troubled about actual or potential problems Mental health
30. Annoyed Being slightly angry or irritated Mental health
31. Self‐esteem Overall feelings about yourself Mental health
32. Mood swings Quick unexplained changes of mood Mental health
33. Self‐harm Thinking about hurting yourself on purpose or wishing you were 
dead
Mental health
34. Concealment Not telling people about epilepsy Mental health
35. Fears of having a seizure Having a seizure in public, being injured during a seizure, dying 
during a seizure, what other people will do during a seizure
Mental health
36. Literacy Reading, writing, spelling Cognition
37. Speech and language Making yourself understood and understanding when spoken to Cognition
(Continues)
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about meeting members available in Appendix S5. Five of 
the voters had not taken part in the Delphi survey but were 
deemed eligible as they had sufficient knowledge of the 
CHOICE project. Twenty‐eight outcomes were voted as 
critical for the COS from the 41 no‐consensus outcomes. 
Overall, 39 outcomes were deemed critical for inclusion 
in the COS split into 10 domains: seizures, sleep, global 
quality of life, mental health, social functioning, physical 
functioning, cognition, behavior, family life, and adverse 
events. An overview of the final COS and its development 
process is shown in Figure 2 and the results of the consen-
sus meeting in Table 4.
4 |  DISCUSSION
This study enabled young people with epilepsy, parents, and 
health professionals from different backgrounds to come to-
gether and reach consensus on important outcomes to measure 
in evaluative research on RE. The 39 outcomes included in the 
COS were rated as “critical” by >70% of people in all three 
stakeholder groups. Using Delphi methodology avoids potential 
overinfluence of one type of stakeholder and captures different 
perspectives. Hence, our COS represents the view shared by 
young people with epilepsy, parents, and various health profes-
sionals working with children with epilepsy. Future research 
evaluating interventions for children with RE should use the 
CHOICE COS as a reference for selecting outcomes and con-
sider its adaptability for other childhood epilepsies.
The CHOICE COS is the result of a transparent process 
that was inclusive of young people and parents, as well as pro-
fessionals in the field of epilepsy. The 39 outcomes across 10 
domains perhaps represent more of a “comprehensive” rather 
than a “core” outcome set (Figure 2). A COS is meant to be 
a minimum set of outcomes to report. Further work could 
consider reducing the number of outcomes by ranking which 
outcomes are of most importance, relevant to each other. We 
did not have enough time during our face‐to‐face meeting to 
undertake a ranking task. The COMET handbook25 identi-
fies examples of where ranking has been used32‒34 as well as 
a recent study from the COMET database conducted in Sri 
Lanka that used a ranking method.10
Our COS captured commonly reported items such as 
“seizure frequency” consistent with existing guidelines.11‒16 
Outcome ID and name in Delphi Description Domain name
38. Memory Short and long term Cognition
39. Concentration Focusing on something for the required period of time Cognition
40. Learning Gaining new skills and knowledge generally Cognition
41. School attendance Attending school and engaging in school curriculum Cognition
42. Academic attainment Reaching personal potential through studying and completing 
assigned tasks and projects, and advancing to next stages of 
education
Cognition
43. Executive functioning The ability to plan and organize activities; executive functions help 
you manage life tasks of all types; for example, executive 
functions let you organize a trip, a research project, or a paper for 
school effectively
Cognition
44. Overall quality of life How you feel your life is generally Global quality of life
45. Adverse events Any unintended effects of treatments, side effects Adverse events
46. Relationships with parents and siblings Getting along well with and feeling close to other members of family Family functioning
47. Family life Impact of epilepsy on family life such as parent work opportunities 
and/or leisure time
Family functioning
48. Parent health Parent's physical and emotional well‐being Family functioning
Outcomes suggested and included in R2
49. Unplanned epilepsy‐related admissions 
to hospital as an inpatient
Unexpectedly needing to be admitted to hospital Adverse events
50. Unplanned hospital attendances at 
Accident and Emergency Department
Visiting the hospital due to an acute medical emergency Adverse events
51. Attendance for medical appointments in 
outpatients
Routine attendances for medical epilepsy management Seizures
52. Drug treatment failure (adverse events or 
poor seizure control)
Stopping medication because it is not working or causing problems Adverse events
T A B L E  1  (Continued)
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However, in contrast, our COS highlights non–seizure‐related 
outcomes such as “school attendance” (attending school and 
engaging in school curriculum) and “feelings about epilepsy” 
(emotions or reactions to having epilepsy such as embarrass-
ment or stigma) agreed as critical for inclusion in the COS. All 
COS outcomes and their definitions are in Table 1. Outcomes 
such as “pain” were not deemed as important for an epilepsy 
COS across the stakeholder groups. This might be a reflection 
of the relevance of that outcome for this specific type of epi-
lepsy.21,35 In the consensus meeting, the young people involved 
were vocal and fairly represented, and their views were often 
persuasive on other participants. The inclusion of more child‐
centered outcomes suggests that the seizure‐centered view is 
not the only important outcome for HRQoL in young people 
with RE. Pragmatically, to inform our trial we are identifying 
and assessing epilepsy‐specific HRQoL measures.
The COMET database included a study conducted in 
Sri Lanka that has developed outcome criteria to measure 
effectiveness of antiepileptic therapy in children, which in-
cluded young people with epilepsy as one of the stakeholder 
groups.10 The study was published while we were in the pro-
cess of conducting our study. Their study recruited 15 young 
people with epilepsy, and the outcomes that reached con-
sensus were very similar to ours, which adds assurance that 
our COS captures outcomes important to young people with 
epilepsy across different settings. For example, their work in-
cluded outcomes such as frequency of seizures, severity of 
seizures, seizure freedom, cognitive function, activities that 
children like to do, school attendance, behavior, and quality of 
life, which map well onto the COS we propose. Interestingly, 
they ranked their outcomes with frequency of seizures being 
most important, followed by quality of life, which might sug-
gest that seizures affect QoL.10
Major strengths of the CHOICE study include a prior defined 
protocol,23 following COMET initiative methodology and using 
the standardized COMET taxonomy.29 The DelphiManager 
software ensured that the views of all three stakeholder groups 
were given equal representation despite varying numbers of 
participants in each group. The DelphiManager survey method 
ensures fair representation, as analysis is assessed within stake-
holder group before comparing across stakeholder groups. This 
is the same method we used in the consensus meeting, as we 
used proportions of stakeholder type to balance representa-
tion and compared within stakeholder group before comparing 
across groups. We included the views of young people with RE, 
their parents, and professionals in the Delphi, and we convened 
APs alongside to ensure PPI input at both the development and 
the implementation stage of the COS.
A potential limitation of our study is that we conducted 
a proportionate rather than a comprehensive systematic re-
view. Systematic reviews are time‐consuming and for the 
purposes of COS development they may not generate addi-
tional outcomes for conditions that are common.25 We did 
use various databases for the review and included a wide 
T A B L E  2  Response of R1 and R2 of the Delphi survey
Stakeholder group Registered interest, n
Round 1, n (% who were eligible to take 
part)
Round 2, n (% who were 
eligible to take part)
Professionals total 120 76 (63) 61 (80)
Pediatricians 51 33 (65) 26 (82)
Pediatric neurologists 16 14 (88) 12 (86)
Epilepsy nurses 22 15 (68) 12 (87)
Consultant in sleep medicine 6 3 (50) 2 (67)
Physiologists 5 4 (80) 3 (75)
Respiratory and sleep physiologists 11 3 (27) 2 (67)
Dietetics lecturer 1 1 (100) 1 (100)
NHS manager 2 2 (100) 2 (100)
Child and adolescent psychiatrist 1 1 (100) 1 (100)
CEO of children's charity 1 0 0
Child health lecturer 1 0 0
Clinical psychologist 1 0 0
Neuropsychologist 2 0 0
Parents 40 23 (58) 16 (67)
Young people 5 3 (60) 3 (100)
Total 165 102 (62) 80 (78)
Note. One professional withdrew. Four people did not answer fully in R1. Twenty‐two people did not fully answer in R2. 
Abbreviation: NHS, National Health Service.
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T A B L E  3  R1 & R2 percentage of scores for 7‐9 (critical for inclusion) across all three stakeholder groups
Outcome Round 1 Round 2
 Professionals, n = 76 Parents, n = 23
Young people, 
n = 3 Professionals, n = 61 Parents, n = 16
Young 
people, n = 3
1. Seizure freedom
 85% 83% 67% 94% 88% 67%
2. Seizure frequency
 91% 91% 67% 95% 94% 100%
3. Seizure duration
 63% 87% 67% 73% 94% 100%
4. Seizure severity
 77% 87% 33% 89% 100% 33%
5. Time to fall asleep
 35% 22% 0% 19% 35% 0%
6. Time spent asleep
 55% 39% 0% 48% 71% 0%
7. Waking from sleep
 59% 39% 67% 55% 76% 67%
8. Breathing difficulties during sleep
 54% 65% 67% 55% 75% 67%
9. Daytime sleepiness
 65% 39% 67% 73% 47% 67%
10. Fatigue
 55% 35% 33% 52% 53% 33%
11. Pain
 37% 57% 0% 26% 56% 0%
12. Coordination and balance
 40% 52% 100% 41% 59% 100%
13. Movement ability
 27% 30% 67% 26% 31% 67%
14. Manual ability
 31% 35% 33% 26% 47% 33%
15. Self‐care
 42% 30% 33% 28% 41% 33%
16. Ability to join in activities with others
 59% 48% 67% 64% 59% 67%
17. Ability to play on one's own
 45% 26% 67% 36% 35% 67%
18. Friendships
 58% 52% 67% 62% 53% 67%
19. Engagement in school life
 74% 57% 67% 75% 59% 67%
20. Social life
 64% 52% 33% 67% 65% 33%
21. Experience of other people's attitudes toward epilepsy
 49% 43% 67% 46% 50% 67%
(Continues)
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Outcome Round 1 Round 2
 Professionals, n = 76 Parents, n = 23
Young people, 
n = 3 Professionals, n = 61 Parents, n = 16
Young 
people, n = 3
22. Behaving appropriately
 56% 61% 67% 57% 71% 67%
23. Impulsivity
 42% 48% 67% 46% 65% 100%
24. Fidgeting
 38% 43% 33% 38% 65% 33%
25. Feeling normal
 68% 61% 33% 79% 65% 33%
26. Feelings about having epilepsy
 68% 74% 33% 70% 65% 33%
27. Happiness
 67% 64% 100% 79% 65% 100%
28. Sadness
 65% 61% 33% 66% 63% 33%
29. Worried
 67% 57% 67% 67% 63% 67%
30. Annoyed
 49% 52% 100% 46% 69% 100%
31. Self‐esteem
 69% 65% 67% 77% 69% 100%
32. Mood swings
 60% 52% 67% 54% 69% 100%
33. Self‐harm
 68% 59% 50% 70% 75% 67%
34. Concealment
 57% 52% 33% 49% 56% 33%
35. Fears of having a seizure
 74% 74% 100% 84% 81% 100%
36. Literacy
 57% 57% 67% 66% 81% 67%
37. Speech and language
 66% 57% 33% 67% 69% 33%
38. Memory
 72% 65% 67% 72% 81% 67%
39. Concentration
 72% 65% 100% 79% 81% 100%
40. Learning
 79% 74% 100% 80% 94% 100%
41. School attendance
 70% 48% 67% 77% 50% 67%
42. Academic attainment
 63% 52% 67% 72% 69% 100%
T A B L E  3  (Continued)
(Continues)
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range of studies23; we also provided opportunities for AP 
and survey participants to suggest any outcome domains not 
identified in the review. It is evident from the review results 
that a large number of varied outcomes have been used in 
epilepsy research, which demonstrates the important chal-
lenge of developing an agreed‐upon COS. We encountered 
difficulties in recruiting RE patients to the CHOICE Delphi 
study, particularly that the term “rolandic” was unfamiliar 
to many families. Our participant information sheets and 
adverts used rolandic as well as the ILAE term “childhood 
epilepsy with centrotemporal spikes.”
The CHOICE study is a work package within a larger 
program of work called “Changing Agendas on Sleep 
Treatment and Learning” (CASTLE; http://castlestudy.org.
uk), and decisions were made to reduce to two rounds rather 
than three in the Delphi survey to deliver the COS in time 
to inform design of the clinical trial. The impact of this 
meant that participant burden was lessened, which perhaps 
is a reason we had little attrition between the two rounds. 
However, a three‐round Delphi would have possibly meant 
a larger sample of people may have reached consensus on 
more items.
The number of participants in our survey, particularly young 
people, was low despite our varied approach to recruitment. 
However, the three young people who took part in R1 of the 
survey also took part in R2. Attrition rates overall were good for 
the survey, with 78% of those who took part in R1 taking part 
in R2. This was despite the survey only being open for 2 weeks 
for each round. However, even with multiple email reminders, 
some telephone calls were needed to improve the response 
rate. Clinical work load and school term time, as well as the 
short window that the rounds were open for, are likely to have 
contributed to the time it took for participants to respond. The 
number of people in each stakeholder group who were able to 
attend the consensus meeting after participating in the online 
Delphi was lower than expected based on the number invited. 
The meeting was held on a weekday during school time, and 
parents and health professionals may have had different prefer-
ences for the timing of the meeting; specific needs such as clinic 
times for professionals and childcare needs should be taken into 
consideration for future studies.
The analysis of the Delphi results grouped professionals 
into one stakeholder group. We decided to group profession-
als due to small numbers in some professions. However, the 
Outcome Round 1 Round 2
 Professionals, n = 76 Parents, n = 23
Young people, 
n = 3 Professionals, n = 61 Parents, n = 16
Young 
people, n = 3
43. Executive functioning
 63% 48% 100% 67% 69% 100%
44. Overall quality of life
 92% 74% 67% 93% 88% 67%
45. Adverse events or reactions
 71% 78% 67% 72% 81% 67%
46. Relationships with parents and siblings
 58% 48% 100% 61% 63% 100%
47. Family life
 62% 48% 67% 64% 56% 67%
48. Parental health
 51% 43% 67% 46% 50% 67%
49. Unplanned epilepsy‐related admissions to hospital as inpatient
    70% 67% 67%
50. Unplanned hospital attendances at Accident and Emergency Department
    70% 64% 33%
51. Attendance for medical appointments in outpatients
    33% 44% 0%
52. Drug treatment failure (adverse events or poor seizure control)
    78% 87% 100%
Note. Green highlight indicates >70% of participants rated as 7‐9 (critical for inclusion). Yellow highlight indicates >50% of participants rated as 7‐9 (critical for 
inclusion).
T A B L E  3  (Continued)
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varying roles of stakeholders may have had some influence 
on the level of engagement with a COS of children with RE. 
For example, the majority of professionals were epilepsy spe-
cialist nurses, pediatric neurologists, and pediatricians, and 
the smaller numbers were seen in lecturers and NHS man-
agers. Voting in the consensus meeting was not conducted 
anonymously, because we wanted to seek consensus by hav-
ing active discussion about shared or differing opinions and 
for participants to consider how other stakeholders voted.
The CHOICE COS focused principally on RE as an exem-
plar of childhood epilepsy. Focusing on RE avoided preferences 
for outcomes that might be affected by including children who 
have associated conditions such as autism or cerebral palsy. 
However, we suggest that the CHOICE COS could poten-
tially be generalized across other childhood epilepsies. Future 
work could consider the extent to which any variations might 
be necessary to validate the COS in other childhood epilepsy 
syndromes. The scope of our work was primarily UK‐based, 
F I G U R E  2  Overview of core outcome set (COS) development and final COS. 
Abbreviation: A&E, Accident and Emergency Department
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T A B L E  4  Summary of consensus meeting voting results
Outcome
Number of stakeholder 
groups (of 3) achieving 
consensus prior to meeting
% of 15 meeting partici-
pants voting as critical 
for inclusion in COS
% of meeting 
participants voting 
as not critical
Category of meeting 
conclusion
Seizure freedom 3 100 0 1
Seizure frequency 3 100 0 1
Seizure duration 3 100 0 1
Seizure severity 2 100 0 2
Time to fall asleep 0 0 100 4
Time spent asleep in 24 hours 1 100 0 3
Time spent asleep each night 1 100 0 3
Awakenings from sleep 2 100 0 2
Breathing difficulties during 
sleep
2 93 6 2
Daytime sleepiness 2 93 6 2
Fatigue 0 0 100 4
Pain 0 0 100 4
Movement ability–gross 
motor function
1 100 0 3
Manual ability–fine motor 
function
1 93 6 3
Self‐care 0 0 100 4
Ability to join in activities 
with others
1 100 0 2
Ability to play on one's own 1 0 100 4
Friendships 1 93 7 2
Engagement in school life 2 100 0 2
Experience of other people's 
attitudes toward epilepsy
1 100 0 2
Behavioral concerns 2 100 0 3
Impulsivity 1 79 21 2
Fidgeting 0 0 100 4
Feelings about having epilepsy 2 100 0 3
Self‐harm 3 100 0 1
Fears of having a seizure 3 100 0 1
Self‐esteem 2 100 0 2
Mood swings 1 100 0 2
Concealment 0 100 0 2
Learning 3 100 0 1
Concentration 3 100 0 1
Literacy 2 100 0 2
Memory 3 100 0 1
Speech and language 0 93 7 2
School attendance 2 100 0 2
Academic attainment 2 100 0 2
Executive functioning 1 100 0 2
Relationships with parents and 
siblings
1 100 0 2
(Continues)
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but the COS may have broader international relevance. To pro-
mote uptake of the suggested COS internationally, an interna-
tional consensus would be needed.
Having decided which outcomes to measure, the next step 
in the COS process is to decide how best to measure each 
of these outcomes and how to define them using published 
guidance.36 The time burden for research participants will 
need consideration for the comprehensive outcome list we 
currently propose. Although further work is necessary to re-
duce the COS and define the outcomes further, our next step 
will be to identify and assess the measurement properties of 
epilepsy‐specific HRQoL measures to inform the CASTLE 
trial and assess whether the outcomes we propose are mea-
sured by these instruments. We will consult guidelines on 
the selection of outcome measurement instruments for a 
COS developer by COSMIN (Consensus‐Based Standards 
for the Selection of Health Measurement Instruments).36
5 |  CONCLUSIONS
We recommend that future evaluative research in RE consid-
ers utilizing the CHOICE COS as a framework for selecting 
outcomes for evaluative research. The CHOICE COS is a fair 
representation of the views of young people with RE, their 
parents, and professionals and has used established method-
ology.25 Further work to reduce the COS to a smaller number 
of outcomes by ranking will make the COS more managea-
ble. However, we propose that our work toward a COS helps 
advance research in childhood epilepsies. We hope that the 
utilization of outcomes suggested by this COS as a frame-
work in future studies will reduce reporting bias and allow 
for evidence to be synthesized across different studies.
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